Introduction
============

Glioblastoma multiforme (GBM) is the most common primary neoplasm of the brain, which affects approximately 10,000 people every year in the United States (Central Brain Tumor Registry of the United States 2004--2005). It is a very aggressive tumor (WHO grade IV), with a historical survival of less the one year, which has changed little over the last two decades ([@b51]). Multiple attempts have been made to identify effective treatment, leading to the recognition of focal radiotherapy and adjuvant chemotherapy with alkylating agents as modalities which modestly improve patient survival ([@b70]; [@b71]; [@b72]). However, the protective environment of the CNS limits the delivery of the chemotherapy agents inside the brain tumor, with many drugs failing to achieve therapeutic concentrations at the tumor site, even while the systemic levels are at toxic range.

In order to achieve effective local delivery with minimal systemic side-effects different approaches are currently employed, such as administration of therapeutic molecules via intracranially implanted catheters, convection-enhanced drug delivery, or administration through controlled-release polymers ([@b60]). The first of these new agents to be approved by the United States Food and Drug Administration (FDA) for the treatment of malignant gliomas is the 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU, carmustine) implant, also known as the Gliadel^®^ (MGI Pharma, Inc.) wafer.

Preclinical data show that the interstitial release of BCNU leads to superior survival when compared with systemic administration in gliosarcoma intracranial models ([@b73]), with minimal release of the BCNU in the systemic circulation ([@b16]). Among the numerous polymer matrices studied, polifeprosan 20, a copolymer of 1,3-bis-(p-carboxyphenoxy) propane and sebacic acid in a 20:80 molar ratio, was proven to be the most appropriate for BCNU delivery, due to the fact that it protected the BCNU from hydrolytic degradation before release ([@b22]), and was safe in primate brain when given with focal radiation ([@b6]).

In phase 1 and 2 clinical trials the BCNU wafers were well tolerated, with a complication rate acceptable when compared with that of the patients receiving placebo wafers, and demonstrated activity against new and recurrent malignant gliomas ([@b4], [@b3]; [@b53]). Results of these trials showed that BCNU delivery from the polifeprosan 20 wafers is well tolerated, and has established a safe dose of 7.7 mg of BCNU per wafer (3.85% carmustine loading) ([@b53]). At this dose, the local side-effects such as brain necrosis and edema are rare, and there is minimal, if any, systemic toxicity ([@b4], [@b3]; [@b53]).

The BCNU wafers were also evaluated in three randomized phase III studies, the initial one focusing on recurrent malignant gliomas ([@b5]), and the subsequent two in newly diagnosed patients with malignant gliomas ([@b75]; [@b80]). All three clinical trials demonstrated a statistically significant survival advantage for the patients in the BCNU wafers groups. On the basis of these results, the BCNU wafers received FDA approval for patients with recurrent or newly diagnosed anaplastic astrocytomas and glioblastoma multiforme. This article reviews the mechanism of action of BCNU, the preclinical development of the BCNU wafers for interstitial delivery, and summarizes the results of the clinical trials of BCNU wafers for the treatment of malignant gliomas and other intracranial malignancies.

Background
==========

More then 40 years ago studies carried by the National Cancer Institute led to the development of the initial nitrosurea compounds shown to have activity in animal cancer models ([@b35]), with the first successful formulation being 1-methyl-3-nitro-1-nitrosoguanidine ([@b69]). The interest in finding more active analogs led to the discovery in 1963 of 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU, carmustine), an agent proven to be highly effective not only in the intraperitoneal L1210 murine leukemia, but also in the treatment of intracerebral L1210. This activity in the intracranial site was felt to be secondary to its ability to cross the blood--brain barrier ([@b66]). One year later, BCNU was introduced in clinical trials ([@b45]; [@b78]) and was approved by the FDA in March 1977 for the treatment of brain tumors, Hodgkin's disease, and other hematologic malignancies. This led to one of the first effective therapies for human malignant gliomas in clinical trials ([@b9]; [@b30]; [@b70]), with a survival advantage of 2 months compared with patients who received radiation alone ([@b71]). At the same time, BCNU toxicity secondary to systemic administration became well described, with frequent dose-limiting delayed hematologic toxicity ([@b14]), non-dose-dependent pulmonary fibrosis ([@b11]; [@b43]), and secondary acute leukemia in 5%--10% of the patients ([@b10]; [@b50]). Further research work also showed that the systemic and intrathecal delivery of BCNU produced penetration for a very short distance (2 mm from the ependymal surface) and started the quest for better delivery systems ([@b2]).

Direct administration of BCNU through a catheter inserted in the surgical cavity was initially attempted in 1975, with no clear success, presumably secondary to the short half-life of BCNU in solution ([@b45]) and to the limited delivery to the tumor tissue ([@b28]).

Biodegradable polymer wafers for the delivery of BCNU in malignant gliomas were developed by Henry Brem and his group, starting in the late 1980s ([@b85]). This delivery system was proven superior to the systemic administration in animal models, and demonstrated limited systemic toxicity ([@b73]), providing the rationale for evaluation in patients.

Pharmacology and preclinical data
=================================

BCNU mechanism of action, pharmacokinetics, and activity
--------------------------------------------------------

Though considered to be an alkylating agent, BCNU differs from the other derivatives by having several reaction sites in addition to the carbon--chlorine bond, which are able to interact with a variety of reagents under physiological conditions ([@b45]). Its cytostatic properties are secondary to its inhibitory effects at multiple levels, such as DNA ([@b38]), RNA ([@b31]) and protein synthesis ([@b58]; [@b78]). In vitro, BCNU has shown activity against cell lines derived from numerous malignancies, including leukemia ([@b67]), lung cancers, sarcomas, and gliomas ([@b7]).

The main BCNU effect is mediated by its chloroethyl moieties, which can alkylate reactive sites on nucleoproteins ([@b83]), and interfere with DNA synthesis and repair ([@b78]). DNA cross-linking occurs in two steps: chloroethylation of a nucleophilic site on one strand, and displacement of a chloride ion on the other strand, resulting in formation of an ethyl bridge between the strands, which blocks the DNA unwinding, and consequently DNA and RNA synthesis ([@b38]). The high alkylating activity of BCNU is also the cause of its main side-effects, interstitial pneumonitis, due to the DNA injury to the alveolar lining cells ([@b79]) and suppression of hematopoeisis ([@b44]). Another mechanism of activity is the carbomoylation of nucleoprotein lysine residues, with subsequent decrease in RNA and protein synthesis. The importance of this process in the antitumor effect of BCNU is still debated ([@b36]).

After both oral and intravenous administration, BCNU has a very short life, with the parent drug not being detectable after 5 minutes ([@b52]), and its active metabolites being detected in urine up to 72 hours after the initial dose. Both the parent drug and its metabolites rapidly enter the cerebrospinal fluid (CSF) ([@b15]). The preclinical studies also showed wide distribution, with good CSF penetrance ([@b45]), and activity in transplanted gliomas, ependymoblastomas, and astrocytomas ([@b68]). However, BCNU penetration inside the brain tissue was just for a very short distance (2 mm from the ependymal surface) ([@b2]).

BCNU interstitial delivery with biodegradable matrices
------------------------------------------------------

A number of different polymers were studied in order to determine their bio-compatibility and to be able to achieve the graduated, controlled release of BCNU in the tumor tissue. A direct comparison between ethylene-vinyl acetate copolymer and the poly(carboxyphenoxy-propane/sebacic acid) matrices in rats showed that both polymers were well tolerated, and effective in delivering the BCNU, with a significant increase in animal survival ([@b73]). The poly(carboxyphenoxy-propane/sebacic acid) matrix was chosen as the foundation for the Gliadel^®^ wafers. Pharmacological studies showed that the Gliadel^®^ wafers release BCNU in vivo over a period of 21 days, the majority of the drug release taking place in the first 5--7 days ([@b32]; [@b16]), and degrade completely over a period of 6--8 weeks, with the polymer degradation products being eliminated through the urine ([@b32]; [@b84]; [@b12]). The BCNU-polifeprosan 20 wafers allowed delivery of BCNU at high concentrations up to 12 mm from the polymer site in animal models ([@b32]), while distant regions of the brain are exposed only to very low concentrations ([@b22]).

Mechanism of resistance
-----------------------

The resistance to BCNU is complex, due to the fact that at least two types of DNA lesions are created: chloroethyl adducts at O^6^-guanine and interstrand cross-links ([@b17]). The repair of the chloroethyl adducts is conducted by O^6^-alkylguanine-DNA alkyltransferase (AGT or MGMT). AGT activity has been proven to be a major factor in the resistance to BCNU and to other alkylating agents including methylators, as cells that have a low level of AGT are sensitive to alkylating agents, while cells expressing high levels are resistant ([@b57]; [@b26]; [@b34]). The administration of O^6^-substituted guanines such as O^6^-benzylguanine (O^6^BG) can effectively deplete the AGT and restore cell sensitivity to BCNU in both cell cultures ([@b24]) and xenograft models of malignant gliomas ([@b21]).

The repair of the second type of lesions, DNA interstrand cross-links, needs the presence of nucleotide excision repair and homologous recombination factors ([@b48]), but the contribution of these repair mechanisms to BCNU resistance is not well understood.

Clinical experience with Gliadel^®^ in malignant gliomas
========================================================

Initial phase I studies
-----------------------

### Recurrent malignant gliomas

The initial phase I study to determine the optimal concentration of BCNU was done in patients with recurrent malignant glioma ([@b4]). The study enrolled 21 patients divided into 3 sequential groups to receive up to 8 wafers of increasing BCNU concentrations (1.93%, 3.85%, and 6.35%). All the patients had maximum tumor resection at the time of placement of the BCNU wafers. The three groups had similar demographics, but the first two groups had 60% GBM patients, while the highest dose group contained only GBM patients. All three concentrations had similar local side-effects, with 13 out of the 21 patients having new areas of contrast enhancement around the resection cavity at least 7 weeks after the surgery and 10 patients out of 21 needed surgeries for decompression and removal of necrotic tissue. No systemic side-effects were noted. The post-implant and overall survival were higher in the two lower-dose groups then in the high-dose group, which can be at least partially explained by the higher percentage of patients with GBM in the third group. In consequence, the 3.85% BCNU was chosen as the standard dose to be used in the phase III clinical trials and marketing.

A second escalation study in recurrent malignant gliomas was conducted by the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium ([@b53]). This study enrolled 44 patients with recurrent disease, all of which had received prior external beam radiation. These patients were divided in 5 cohorts to be implanted with wafers containing 6.5%, 10%, 14.5%, 20%, and 28% BCNU concentration per 200 mg wafer. In the 6.5 %, 10%, and 14%, no dose-limiting toxicities were observed, and the adverse events (subdural collection, CSF leak, sepsis, and wound infection) were regarded to be similar to those in the patients subjected to tumor re-resection alone. The 20% dose cohort also had similar side-effects (seizures, brain edema, wound infection, wound drainage, and a bone flap infection). However, three out of the four patients enrolled in the 28% dose cohort developed major brain edema and seizures, and the 20% dose level was confirmed as the maximum tolerated dose. However, at the 20% dose level, the BCNU concentration in the blood reached 27 ng/mL at 4 hours after delivery. No systemic toxicities were included in this study report.

### Newly diagnosed malignant gliomas

A phase I trial was also conducted in the newly diagnosed gliomas at the same institutions involved in the initial phase I study for recurrent gliomas ([@b3]). This trial enrolled 22 patients who received maximum resection, placement of seven to eight wafers impregnated with 3.85% BCNU, and subsequent standard external beam radiation. Ten of the 22 patients experienced severe adverse-effects in the postoperative period, such as seizures, neurologic decline, brain necrosis, infection, and deep venous thrombosis. Nine patients needed a secondary craniotomy after an average of 34 weeks, but 8 had recurrent tumor and only 1 necrosis. The median survival was 42 weeks.

Phase I and III clinical experience
-----------------------------------

Based on the safety data from the phase I and II clinical trials, and the need for improved treatment in malignant gliomas, a series of phase III clinical trials were conducted.

### Recurrent malignant gliomas

The initial phase III study ([@b5]) enrolled 222 patients with recurrent malignant glioma who had an unilateral single focus of recurrent tumor of at least 1 cm^3^, a KPS \>60%, and no recent treatment with nitrosureas. Patients were implanted with either the carmustine polymer or the placebo polymer disks. The dose of carmustine on the polymer disks was 7.7 mg per wafer (3.85% BCNU). The median survival for the combined pathology (anaplastic astroccytoma and glioblastoma multiforme) was 31 weeks in the carmustine group and 23 weeks in the placebo group (survival advantage of 8 weeks). For the patients diagnosed with glioblastoma multiforme the 6 months survival was 56% in the carmustine group and 47% in the placebo group (p = 0.061). The only complication more frequently seen in the treatment group was serious intracranial infection. Based on the results of this study US-FDA approval of Gliadel^®^ for the treatment of recurrent patients was obtained in 1996.

### Newly diagnosed malignant gliomas

The first phase III study of carmustine loaded polymers for newly diagnosed patients ([@b75]) enrolled 32 newly diagnosed patients (initial enrollment planned for 100 patients) with grade III and IV gliomas. The inclusion criteria required unilateral disease greater than 1 cm^3^, not crossing the midline, and good performance status. The patients were randomized to receive BCNU or placebo wafers, after which they underwent standard focal beam radiation therapy. No indication of adjuvant treatment was provided. The time from surgery to death was the primary endpoint, with a median survival time of 58.1 weeks for BCNU vs 39.9 for placebo, with a survival advantage of 18 weeks (p = 0.012). The adverse effects were comparable between these two groups, and included wound infection, septic inflammation with meningismus, CSF leukocytosis with hydrocephalus, deep venous thrombosis with pulmonary thromboembolism, pneumonia, visual disturbances, and hemiparesis.

A larger phase III study to confirm the previous data enrolled 240 patients from 38 centers in 14 countries ([@b80]). The patients were again randomized to be implanted with BCNU vs placebo wafers, followed by focal radiation, while adjuvant systemic chemotherapy was explicitly prohibited until the time of tumor recurrence. The patient follow-up reported in this study was between 12 and 30 months. The median survival in the intent-to-treat group (grade III and IV tumors) was 13.9 months for the patients receiving BCNU wafers vs 11.6 months for the placebo group (p = 0.03). The GBM subgroup multivariate analysis showed that BCNU wafers prolonged survival in the treatment group, after correction for prognosis factors (p = 0.04), with a risk reduction of 31% (95% CI, 3%--51%). More CSF leaks and increased intracranial pressure secondary to mass effect and edema were seen in the BCNU-wafer-treated group. It is important to mention that this study had targeted a selected population, as a retrospective review of the patients enrolled from the Edinburgh center showed that only 25% of the patients with malignant glioma could be enrolled in the trial, and that they were younger, had better performance status, and were more likely to have tumor resection and postoperative radiotherapy ([@b82]).

A long-term report (56 months follow-up period) including data on the patients still alive at the time of publication of the phase III study confirmed a median survival of 13.8 months vs 11.6 months (p = 0.017) in favor of the BCNU-wafer-treated group, and a continuous survival advantage at 1, 2, and 3 years ([@b80]). The report of the pattern of recurrence in a subgroup of 24 patients from the Westphal study showed a time to progression of 165 days for the patients in the BCNU wafers group vs 101 days for the placebo group (p = 0.023) ([@b29]). All the patients receiving BCNU wafers eventually had recurrent tumor, with 73% of the patients having recurrent tumor adjacent to the resection cavity, and 27% having both local and distal recurrences.

A meta-analysis combining two phase III clinical trials for newly diagnosed patients ([@b75]; [@b80]) has also been reported ([@b49]). The meta-analysis included all the patients diagnosed with GBM, and reported a median survival for the Gliadel^®^ group of 13.1 months vs 10.9 months for the placebo group (p = 0.031), and a hazard ratio of 0.71 (p = 0.019) at the multivariant analysis, which translates in a 29% reduction in the risk of dying. The results of this meta-analysis led to the FDA approval of Gliadel^®^ for newly diagnosed high grade glioma patients in 2003.

Complications
-------------

A number of complications related to the Gliadel^®^ wafers were identified during the phase III clinical trials, but the rate was similar to that in patients receiving placebo wafers ([@b75]; [@b80]). However, in clinical practice following the drug approval, more treatment-related complications were identified, as the treatment was extended also to patients who were not eligible in the initial studies.

The rate of postcraniotomy surgical infection after BCNU wafer placement was reported to be as high as 28%, and is correlated with inadequate antibiotic prophylaxis ([@b47]). Extensive cerebral edema was also reported after Gliadel^®^ placement, and led to severe neurologic compromise and death ([@b76]). Another cause of severe toxicity and death with Gliadel^®^ wafers recently reported is obstructing hydrocephalus, and the authors of the case-report concluded that a large opening of the ventricle during surgery might be considered a contraindication for wafer placement ([@b27]).

Local treatment effects, such as pericavity necrosis are also commonly seen, affecting 11% of all patients, and 33% of the patients undergoing re-operation for radiological progression, which it makes difficult to differentiate between tumor recurrence and treatment effect based on non-invasive studies ([@b37]). Other observations following Gliadel^®^ implantation include the formation of tumor bed cysts with new neurologic symptoms secondary to mass effect. This complication has been addressed successfully with either high dose steroids or surgical decompression depending on the degree of mass effect ([@b46]).

Overcoming resistance -- combination trials
-------------------------------------------

Due to the clear survival advantage in a well defined group of patients with new and recurrent malignant gliomas, new strategies were developed in order to augment the therapeutic effect of the BCNU wafers by decreasing the tumor resistance to alkylating agents mediated by AGT or by combining the BCNU wafers with either systemic chemotherapeutic agents such as temozolomide, carboplatin, PCV, and irinotecan or other interstitial therapies such as interleukin-2, iodine-125 seeds, GliaSite^®^ (Cytyc Corp.), and radiosurgery ([@b1]).

Gliadel^®^ and O^6^Benzylguanine (O^6^BG)
-----------------------------------------

The initial work in animal models showed that O^6^BG can potentiate the activity of carmustine wafers by inhibiting the activity of AGT, a DNA repair enzyme involved in tumor resistance to alkylating agents including BCNU, and prolong animal survival ([@b62]). The initial trial of O^6^BG in patients with brain tumors demonstrated suppression of AGT activity when O^6^BG was administered at a dose of 120 mg/m^2^ 18 hours before surgery ([@b25]). Built on this, a phase I trial of Gliadel^®^ combined with O^6^BG has demonstrated that the combination is well tolerated when O^6^BG is administred as a 120 mg/m^2^ bolus 1 hour before surgery, followed by continuous infusion at 30 mg/m^2^/day for up to 7 days ([@b77]). The phase II clinical trial of Gliadel^®^ plus O^6^BG in recurrent glioblastoma multiforme patients from our institution ([@b59]) used a 120 mg/m^2^ bolus over 1 hour administered after surgery, and on day 3 and 5 simultaneously with a 5-day infusion at 30 mg/m^2^/day. Preliminary results indicated a 80% 6-month survival and 47 weeks median survival, which is significantly better compared with 56% 6-month survival and 31 weeks median survival in the original Brem study. The adverse effects were similar to those described with Gliadel^®^ alone ([@b59]).

Combination treatment with systemic chemotherapy
------------------------------------------------

Gliadel^®^ and temozolomide were shown in separate studies to prolong patient's survival, leading to a phase I study to determine the optimal dose of temozolomide to be used in patients with recurrent gliomas who had prior placement of Gliadel^®^ wafers. Patients tolerated doses up to 200 mg/m^2^ for 5 days given every 4 weeks, with only 1 patient developing grade III thrombocytopenia, and 2 out of 10 patients had no tumor recurrence after 1 year ([@b33]). A phase II multicenter clinical trial is currently underway for patients with newly diagnosed malignant gliomas ([@b40]). The patients enrolled had resection and Gliadel^®^ insertion, followed by focal beam radiation with concomitant daily temozolomide (at 75 mg/m^2^), followed by monthly temozolomide (5-day regimen, at 200 mg/m^2^). At the last report, 33 patients were enrolled, with a median follow-up of 8.1 months. The median survival is 18.5 months, and the median progression-free survival is 6.4 months.

A second phase I study combined Gliadel^®^ wafer implantation with immediate postoperative carboplatin followed by radiation therapy in patients with newly diagnosed malignant gliomas. Carboplatin dose was calculated based on Calvert formula, where the dose of carboplatin (mg) = target area under the carboplatin concentration curve vs time curve (AUC) × glomerular filtration rate + 25. The maximum tolerated dose for carboplatin which was administered on either day 3 or 4 after surgery corresponded to an AUC of 6. No toxicities were seen ([@b42]).

The combination of Gliadel^®^ and PVC (procarbazine, lomustine, and vincristine) chemotherapy in newly diagnosed patients with malignant glioma was explored in the context of a phase I/II clinical trial ([@b39]). Though a small study (9 patients enrolled), the combination seems to be tolerated, and possibly effective.

Our group has conducted a retrospective study to determine if Gliadel^®^ wafer insertion at the time of initial surgery benefited patients receiving radiation therapy with concurrent temozolomide, followed by rotational multi-agent chemotherapy (temozolomide, CCNU, CPT-11) ([@b63]). In this study, a difference in survival was found between the patients that had Gliadel^®^ wavers vs those that had surgery alone.

Finally, in recurrent patients with glioblastoma multiforme, the toxicity and efficacy of the combination of Gliadel^®^ and intravenous irinotecan was reported ([@b64]). In the 10 patients enrolled, the combination was well tolerated and possibly more effective then monotherapy.

Combination treatment with local chemotherapy
---------------------------------------------

The combination of Gliadel^®^ and permanent I-125 Seeds was addressed in 4 different clinical trials enrolling recurrent malignant glioma patients ([@b23]; [@b74]; [@b13]; [@b86]). The combination was safe, and the major complication was radiation necrosis (up to 24% of the patients). The largest of these studies ([@b13]) enrolled 34 patients with recurrent glioblastoma, and reported a progression-free survival of 47 weeks, and overall survival of 73 weeks, which compares favorably with the published data on Gliadel^®^ monotherapy ([@b5]).

Consecutive use of brachytherapy (Gliasite^®^) and Gliadel^®^ was studied in a phase I/II study which enrolled 27 patients with recurrent glioblastoma ([@b65]). The overall median survival was 27 weeks, and the complications were rare, but included 1 death (intracranial hemorrhage) and 4 thrombotic events (DVT).

Only animal data are available at this time evaluating the combination of BCNU wafers with local administration of interleukin-2 (IL-2). In the rodent model, the animals that received an intracranial implant of microspheres containing IL-2, followed 5 days later by BCNU wafers showed superior survival compared with the animals that received either one of the two drugs alone or the placebo implants ([@b61]).

Other tumors
============

Pituitary adenomas, craniopharingiomas, and esthesioblastoma
------------------------------------------------------------

The results of a phase I feasibility study from University of Virginia show that Gliadel^®^ is a reasonable option in the treatment of non-glial intracranial tumors such as pituitary adenomas and craniopharyngiomas. Among the 10 patients enrolled in this study, 7 were still alive after a mean follow-up of 19 months, with 4 patients free of recurrent tumor, and 2 with stable disease ([@b41]). No side-effects such as CSF leaks were observed in this population, though more than half the patients have received either stereotactic radiosurgery or conventional focal radiation to the tumor bed.

A case report was also published about the use of carmustine wafers in the treatment of esthesioblastomas, with good local control and minimum complications ([@b54]). More research needs to be done in order to be able to conclude that this treatment is efficacious in the treatment of this rare tumor.

Metastatic brain tumors
-----------------------

Animal studies from Brem's group show that Gliadel^®^ in combination with radiation is effective against the four metastatic tumor models tested in the initial study: lung carcinoma, renal cell carcinoma, colon carcinoma and melanoma ([@b20]), as well as in a model of breast carcinoma ([@b19]). A newly published phase II study reports on the safety and efficacy of Gliadel^®^ wafers followed by whole-brain radiation for the treatment of single brain metastasis ([@b18]). This treatment achieved superior local control, with zero local recurrences and a rate of distal brain relapse of 16%, similar to other studies of brain metastasis ([@b56], [@b55]). Therapy was well tolerated, with 3 severe side-effects such as seizures and respiratory compromise, and 7 mild or moderate adverse effects (nausea, fever, constipation, and eye pain). The median survival was 33 weeks, with 33% survival at 1 year, and 25% at 2 years.

Summary and conclusion
======================

BCNU polymeric wafers represent an innovative way of delivering chemotherapy directly to the intracerebral high-grade tumors, with no systemic toxicity. Building on the known activity of BCNU as alkylating agent in malignant gliomas, it allows for sequential drug release in a constant and safe manner in the surrounding brain tissue. This method is very well tolerated, with minimal local toxicity.

Clinical trials using Gliadel^®^ have shown that it is a valid option in a selected group of patients with malignant gliomas (good performance status, only one relatively small lesion), in both the new diagnosed and recurrent settings. Recent studies are suggesting that the activity of the BCNU wafers can be improved by administration of agents that overcome resistance to BCNU (such as O^6^-BG), and the results of combination trials with other therapeutic modalities appear promising. More data need to be accumulated in order to have a clear understanding of the role of Gliadel^®^ in the treatment of other intracranial neoplasms, as well as intracranial metastatic disease.

The complications of using the Gliadel^®^ seem to be comparable with those of craniotomy alone, but increased difficulty with wound healing, and rare and potential fatal incidents of malignant brain edema, as well as of chemical meningitis followed by obstructive hydrocephalus, have been reported. Therefore, the survival benefits of Gliadel^®^ placement should be balanced by the clinician with the concern for possible toxicity.

The limitations of the BCNU wafers are directly related to the limited penetrance of BCNU, as most of the tumors recur locally, at a short distance from the wafers. Therefore, it is critical to evaluate valid systemic treatments, which can both address the local and the distant brain involvement, and which can be safely used in this setting. A number of promising multimodal therapies are currently progressing through clinical trials, based on the good safety profile already demonstrated in the combinations studies of different systemic chemotherapeutic agents such as temozolomide, carboplatin, PCV, and carboplatin in patients that have received Gliadel^®^ ([@b1]).

In conclusion, the unique properties of the Gliadel^®^, its lack of systemic side-effects, and its documented safety and efficacy justify its use in malignant gliomas, and its potential applications in other intracranial tumors. Large-scale trials addressing ways to overcome local resistance to BCNU, as well as multi-agent chemotherapy combinations, are currently in different stages. Further work needs to focus in developing better local delivery systems, with improved penetrance in the brain tissue, as well in addressing the multifactorial mechanisms of BCNU resistance, and in attempting the interstitial delivery of improved chemotherapeutic agents.
